Skip to main content
. 2015 Dec 10;48(2):471–484. doi: 10.3892/ijo.2015.3287

Figure 6.

Figure 6

Prognostic impact of p85α protein expression in breast cancer patients. Kaplan-Meier estimates of (A) 5-year DFS and (B) 5-year OS for all patients with p85α overexpression or downregulation. Kaplan-Meier estimates of (C) 5-year DFS and (D) 5-year OS for patients with clinical stage I and II breast cancer. Kaplan-Meier estimates of (E) 5-year DFS and (F) 5-year OS for patients with clinical stage III breast cancer. OS, overall survival; DFS, disease-free survival.